Control genes in international standardization of real-time RT-PCR for BCR-ABL

Leukemia Research

Volumn 33, Issue 4, 2009, Pages 582-584

  Moravcová, Jana ^a   Rulcová, Jana ^a   Poláková, Kateřina Machová ^a   Klamová, Hana ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; BCR ABL PROTEIN; BETA 2 MICROGLOBULIN; BETA GLUCURONIDASE; DASATINIB; IMATINIB;

CANCER REGRESSION; CHRONIC MYELOID LEUKEMIA; DISEASE COURSE; GENE AMPLIFICATION; HUMAN; LETTER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT RESPONSE;

FUSION PROTEINS, BCR-ABL; GENES, ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 60249094152     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.06.020     Document Type: Letter

References (7)

1. Cross N.C.P., Hughes T.P., and Hochhaus A. International standardisation of quantitative real-time RT-PCR for BCR-ABL. Leuk Res 32 (2008) 505-506
2. Rulcová J., Zmeková V., Zemanová Z., Klamová H., and Moravcová J. The effect of total-ABL, GUS and B2M control genes on BCR-ABL monitoring by real-time RT-PCR. Leuk Res 31 (2007) 483-491
3. Gabert J., Beillard E., van der Velden V.H., Bi W., Grimwade D., Pallisgaard N., et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukaemia-a Europe Against Cancer program. Leukemia 17 (2003) 2318-2357
4. Beillard E., Pallisgaard N., van der Velden V.H., Bi W., Dee R., van der Schoot E., et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)-a Europe against cancer program. Leukemia 17 (2003) 2474-2486
5. Bustin S.A. Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): Trends and problems. J Mol Endocrinol 29 (2002) 23-39
6. Hughes T., Deininger M., Hochhaus A., Branford S., Radich J., Kaeda J., et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors-review and recommendations for harmonizing current methodology for detection BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108 (2006) 28-37
7. Hochhaus A., Baccarani M., Deininger M., Apperley J.F., Lipton J.H., Goldberg S.L., et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia (2008) [advance online publication, 10 April]